Last reviewed · How we verify

Primary biliary cirrhosis — Treatment Landscape & Competitive Intelligence

Primary biliary cirrhosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary biliary cirrhosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Actigall URSODIOL AbbVie Bile Acid [EPC] CDGSH iron-sulfur domain-containing protein 1 1987-01-01
Ursolvan Ursolvan Hopital Foch Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. AbbVie · 1 drug in Primary biliary cirrhosis
  2. Hopital Foch · 1 drug in Primary biliary cirrhosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary biliary cirrhosis:

Cite this brief

Drug Landscape (2026). Primary biliary cirrhosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-biliary-cirrhosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing